Publications - Blood Cancer Research WA

A Randomized Phase 3 Trial of Zanubrutinib versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: THE ASPEN STUDY

Load more featured publications

More Publications:

Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Source: Dr David Joske Published on 2020-12-29
Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Source: Dr Dejan Radeski Published on 2020-12-29
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
Source: Dr Dejan Radeski Published on 2020-12-12
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Source: Dr Gavin Cull Published on 2020-12-08
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative.
Source: Dr Carolyn Grove Published on 2020-12-05
Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
Source: Dr Bradley Augustson Published on 2020-11-26
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
Source: Dr Chan Cheah Published on 2020-10-20
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Source: Dr Dejan Radeski Published on 2020-10-08
DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
Source: Dr David Joske Published on 2020-09-17
Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.
Source: Dr Chan Cheah Published on 2020-08-29
Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?
Source: Dr Chan Cheah Published on 2020-08-20
Outcomes and anticoagulation use for elderly patients that present with an Acute Hip Fracture: multi-centre, retrospective analysis.
Source: Dr Carolyn Grove Published on 2020-08-14
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Source: Dr Bradley Augustson Published on 2020-07-31
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
Source: Dr Gavin Cull Published on 2020-07-31
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
Source: Dr Gavin Cull Published on 2020-07-24

Menu